Quark Pharmaceuticals this week announced that its investigational drug for the prevention of delayed graft function in kidney transplant patients has received an orphan drug designation from the European Commission.

The provisions for the EU orphan designation provide incentives to companies developing the products, including the potential for up to 10 years of market exclusivity and various fee reductions for certain regulatory activities, Quark said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.